Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 1, 1997, Pages 294-300

  Sutton, Dylan ^a,b   Butler, Alison M ^a   Nadin, Louise ^a   Murray, Michael ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHOXYCOUMARIN; ADRENALIN; ALPHA NAPHTHOFLAVONE; ANILINE; BISMUTH CITRATE; CEFTRIAXONE; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DESMOPRESSIN; DEXAMETHASONE; DILTIAZEM; DIMETHYLNITROSAMINE; DOPAMINE; DRUG METABOLITE; ENALAPRIL; FLUCLOXACILLIN; IMIPENEM; KETOCONAZOLE; METHYLDOPA; OXAZEPAM; PENICILLIN DERIVATIVE; PRAZOSIN; RANITIDINE; SIMVASTATIN; SUCRALFATE; TESTOSTERONE; TOLBUTAMIDE; TROLEANDOMYCIN; UMBELLIFERONE;

ARTICLE; DEMETHYLATION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG TRANSFORMATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METABOLISM; MICROSOME; PRIORITY JOURNAL;

BIOTRANSFORMATION; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; DILTIAZEM; HUMANS; LIVER; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; TESTOSTERONE;

EID: 0030875423     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. ABERNETHY, D. R. AND MONTAMAT, S. C.: Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. Am. J. Cardiol. 60: 116I-120I, 1987.
2. ASCALONE, V., LOCATELLI, M. AND MALAVASI, B.: Determination of diltiazem and its main metabolites in human plasma by automated solid-phase extraction and high-performance liquid chromatography: A new method overcoming instability of the compounds and interference problems. J. Chromatogr. 657: 133-140, 1994.
3. BRODIE, M. J. AND MACPHEE, G. J. A.: Carbamazepine neurotoxicity precipitated by diltiazem. Br. Med. J. 292: 1170-1171, 1986.
4. CHANG, T. K. H., WEBER, G. F., CRESPI, C. L. AND WAXMAN, D. J.: Differential activation of cyclophosphamide and ifosfamide by cytochrome-P450-B and cytochrome-P450-3A in human liver microsomes. Cancer Res. 53: 5629-5637, 1993.
5. COMBALERT, J., FABRE, I., FABRE, G., DALET, I., DERANCOURT, J., CANO, J. P. AND MAUREL, P.: Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P-450IIIA gene subfamily. Drug Metab. Dispos. 17: 197-207, 1989.
6. HUSSAIN, M. D., TAM, Y. K., FINEGAN, B. A. AND COUTTS, R. T.: Simple and sensitive high-performance liquid chromatographic method for the determination of diltiazem and six of its metabolites in human plasma. J. Chromatogr. 582: 203-209, 1992.
7. KNODELL, R. G., HALL, S. D., WILKINSON, G. R. AND GUENOERICH, F. P.: Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P450 involved in methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Ther. 241: 1112-1119, 1987.
8. KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. AND MEYEB, U. A.: Oxidation of midazolam and triazolam by human liver cytochrome P450 IIIA4. Mol. Pharmacol. 36: 89-96, 1989.
9. LOWRY, O. H., ROSEBROUGH, N. T., FARR, A. L. AND RANDALL, A. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
10. MARRE, F., SANDERINK, G.-J., DE SOUSA, G., GAILLARD, C., MARTINET, M. AND RAHMANI, R.: Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res. 56: 1296-1302, 1996.
11. MONTAMAT, S. C. AND ABERNETHY, D. R.: N-Monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives. Br. J. Clin. Pharmacol. 24: 185-189, 1987.
12. MURRAY, M.: Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. Mol. Pharmacol. 42: 931-938, 1992.
13. MURRAY, M., BUTLER, A. M. AND STUPANS, I.: Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6β-hydroxylation activity by cyclophosphamide and ifosfamide in vitro. J. Pharmacol. Exp. Ther. 270: 645-649, 1994.
14. MURRAY, M. AND REIDY, G. F.: Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev. 42: 85-101, 1990.
15. MURRAY, M. AND RYAN, A. J.: Inhibition and enhancement of mixed-function oxidases by nitrogen heterocycles. Biochem. Pharmacol. 31: 3002-3005, 1982.
16. MURRAY, M., ZALUZNY, L. AND FARRELL, G. C.: Drug metabolism in cirrhosis: Selective changes in cytochrome P-450 isozymes in the choline deficient rat model. Biochem. Pharmacol. 35: 1817-1824, 1986.
17. PENG, R., TENNANT, P., LORR, N. A. AND YANG, C. S.: Alterations of microsomal monooxygenase system and carcinogen metabolism by streptozotocin-induced diabetes in rats. Carcinogenesis 4: 703-708, 1983.
18. PICHARD, L., CURI-PEDROSA, R., BONFILS, C., JACQZ-AIGRAIN, E., DOMBRGUE, J., JOYEUX, H., COSME, J., GUENGERICH, F. P. AND MAUREL, P.: Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol. Pharmacol. 47: 410-418, 1995.
19. PROUGH, R. A., BURKE, M. D. AND MAYER, R. T.: Direct fluorometric methods for measuring mixed function oxidase activity. Methods Enzymol. 52: 372-377, 1978.
20. RENTON, K. W.: Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem. Pharmacol. 34: 2549-2553, 1985.
21. SEGEL, I.: Enzyme Kinetics. Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley and Sons, New York, 1975.
22. SHIMADA, T. AND GUENGERICH, F. P.: Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl. Acad. Sci. USA 86: 462-465, 1989.
23. SHIMADA, T., IWASAKI, M., MARTIN, M. V. AND GUENGERICH, F. P.: Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK1002. Cancer Res. 49: 3218-3228, 1989.
24. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. AND GUENGERICH, F. P.: Inter-individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423, 1994.
25. SUGAWARA, Y., NAKAMURA, S., USUKI, S., ITO, Y., SUZUKI, T., OHASHI, M. AND HARIGAYA, S.: Metabolism of diltiazem. II. Metabolic profile in rat, dog and man. J. Pharmacobiodyn. 11: 224-233, 1988.
26. TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V. AND MINERS, J. O.: Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265: 401-407, 1993.
27. TOYOSAKI, N., TOYO-OKA, T., NATSUME, T., KATSUKI, T. A., TATEISHI, T., YAGINUMA, T. AND HOSODA, S.: Combination therapy with diltiazem and nifedipine in patients with effort angina pectoris. Circulation 77: 1370-1375, 1988.
28. WAXMAN, D. J., ATTISANO, C., GUENGERICH, F. P. AND LAPENSON, D. P.: Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 263: 424-436, 1988.
29. WRIGHTON, S. A. AND STEVENS, J. C.: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22: 1-21, 1992.
30. YUN, C.-H., WOOD, M., WOOD, A. J. J. AND GUENGERICH, F. P.: Identification of the pharmacogenetic determinants of alfentanil metabolism: Cytochrome P-450 3A4. Anesthesiology 77: 467-474, 1992.